The Single Distributor took part in a business meeting in the field of pharmaceuticals between India and Kazakhstan on March 28-29, 2022 as part of a working trip to the city of Almaty.
Recall that on the initiative of the Single Distributor, a round table of pharmaceutical manufacturers in India and Kazakhstan was held to expand cooperation in the pharmaceutical industry. This business meeting is a continuation of bilateral meetings to realize the potential of Kazakhstan as a production site.
About 30 large Indian companies took part in the business meeting, where they presented the investment opportunities of the domestic industry and the terms of benefits, preferences for potential investors, and provided analytical information on the state of the Kazakhstani pharmaceutical market, as well as the role of SK-Pharmacy LLP in the medicine supply system.
The domestic pharmaceutical market today is of great interest to international investors who are looking for new opportunities in emerging markets. According to experts, Kazakhstan has the potential to double the capacity in the pharmaceutical industry. At the end of 2020, Kazakhstan leads in terms of growth in foreign direct investment. Such data are contained in the "World Investment Report" of the United Nations Conference on Trade and Development (UNCTAD).
The Head of the State noted the importance of cooperation with global pharmaceutical corporations, attracting investors, ensuring technology transfer and the latest developments.
As part of the activities carried out to support the development of domestic production of pharmaceutical and medical products, the Single Distributor takes the initiative to provide a platform for major brands to enter the country from packaging to the full production cycle.
Thus, in order to implement measures to develop the pharmaceutical industry in Kazakhstan, SK-Pharmacy holds meetings with major players in the global pharmaceutical industry, during which their long-term plans for presence in the Kazakhstani pharmaceutical market and investment in the industry are discussed.
A powerful incentive for the development of domestic production is the development of interaction with the major global pharmaceutical industry from the TOP-50 BigPharma, and the involvement of domestic research institutes, scientific laboratories of large medical universities like R&D centers, as well as their deployment in free economic and industrial zones.
The Kazakh side noted the great potential for economic cooperation between the two countries, voiced the possibility of building up bilateral cooperation. The parties expressed interest in mutual cooperation and readiness to intensify cooperation in the field of pharmaceuticals and digitalization of the economy. It was noted that it is necessary to consolidate joint efforts for the purpose of mutually beneficial cooperation.
At the same time, within the framework of the working trip, representatives of the Single Distributor visited the existing and new workshop of the production site of Nobel Almaty Pharmaceutical Factory JSC, as well as the production site of Dolce LLP.
Also, during the working trip, inspections of domestic production sites were carried out, they got acquainted with the range of manufactured equipment of MedRemZavod Holding KazMedAspap and Ordamed JSC, where the possibilities of localization and issues of production sharing were discussed.
Recall that the President of the country instructed to switch to a centralized procurement of medical equipment on the basis of the Single Distributor, following the example of the medicines and medical devices procurement.
Currently, a substantive study of the issues of localization of production with foreign and domestic manufacturers of medical equipment is underway. Based on the results of this work, an appropriate list of equipment for localization in Kazakhstan will be formed, which will be worked out in detail by the medical and expert community, together with regional health departments and medical organizations.
.png)
.jpeg)